These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
94 related articles for article (PubMed ID: 2407421)
21. Impact of coronary artery stents on mortality and nonfatal myocardial infarction: meta-analysis of randomized trials comparing a strategy of routine stenting with that of balloon angioplasty. Al Suwaidi J; Holmes DR; Salam AM; Lennon R; Berger PB Am Heart J; 2004 May; 147(5):815-22. PubMed ID: 15131536 [TBL] [Abstract][Full Text] [Related]
22. Eptifibatide and tirofiban: new preparations. Limited benefit. Prescrire Int; 2000 Oct; 9(49):135-8. PubMed ID: 11603412 [TBL] [Abstract][Full Text] [Related]
23. Secondary prevention of vascular disease by prolonged antiplatelet treatment. Antiplatelet Trialists' Collaboration. Antiplatelet Trialists' Collaboration Br Med J (Clin Res Ed); 1988 Jan; 296(6618):320-31. PubMed ID: 3125883 [TBL] [Abstract][Full Text] [Related]
24. [Indications for antiplatelet medications]. Castaigne A; Benacerraf S; Le Roux A Rev Prat; 1999 Oct; 49(15):1635-9. PubMed ID: 10581993 [TBL] [Abstract][Full Text] [Related]
25. Benefits and risks of the combination of clopidogrel and aspirin in patients undergoing surgical revascularization for non-ST-elevation acute coronary syndrome: the Clopidogrel in Unstable angina to prevent Recurrent ischemic Events (CURE) Trial. Fox KA; Mehta SR; Peters R; Zhao F; Lakkis N; Gersh BJ; Yusuf S; Circulation; 2004 Sep; 110(10):1202-8. PubMed ID: 15313956 [TBL] [Abstract][Full Text] [Related]
26. Safety and tolerability of antiplatelet therapies for the secondary prevention of atherothrombotic disease. Spinler SA Pharmacotherapy; 2009 Jul; 29(7):812-21. PubMed ID: 19558255 [TBL] [Abstract][Full Text] [Related]
27. Rebound platelet activation after termination of prasugrel and aspirin therapy due to confirmed non-compliance in patient enrolled in the JUMBO Trial. Serebruany VL; Midei MG; Meilman H; Malinin AI; Lowry DR Int J Clin Pract; 2006 Jul; 60(7):863-6. PubMed ID: 16846403 [TBL] [Abstract][Full Text] [Related]
29. Secondary stroke prevention with antiplatelet drugs: have we reached the ceiling? Diener HC Int J Stroke; 2006 Feb; 1(1):4-8. PubMed ID: 18706062 [TBL] [Abstract][Full Text] [Related]
30. Use of antiplatelet agents and anticoagulants for cardiovascular disease: current standards and best practices. Faxon DP Rev Cardiovasc Med; 2005; 6 Suppl 4():S3-14. PubMed ID: 17710074 [TBL] [Abstract][Full Text] [Related]
31. Clinical studies: evidence for intervention with specific antiplatelet drugs in arterial thromboembolism. Turpie AG Semin Thromb Hemost; 1988 Jan; 14(1):41-9. PubMed ID: 3281264 [TBL] [Abstract][Full Text] [Related]
32. Anti-thrombotic drugs in the treatment of coronary heart disease: the present situation with aspirin. Born GV Z Kardiol; 1990; 79 Suppl 3():147-50. PubMed ID: 2099037 [TBL] [Abstract][Full Text] [Related]
33. [Thrombocyte inhibitors in cardiovascular therapy]. Lüscher TF; Pfisterer M Schweiz Rundsch Med Prax; 1990 Sep; 79(39):1132-41. PubMed ID: 2218249 [TBL] [Abstract][Full Text] [Related]
34. Role of platelets and antiplatelet agents in cerebrovascular disease. Clues from trials. Harrison MJ Circulation; 1990 Jan; 81(1 Suppl):I20-1; discussion I22-3. PubMed ID: 2403864 [TBL] [Abstract][Full Text] [Related]
35. Aspirin in the prophylaxis of coronary artery disease. Mehta P Curr Opin Cardiol; 2002 Sep; 17(5):552-8. PubMed ID: 12357134 [TBL] [Abstract][Full Text] [Related]
36. A new way of targeting to treat coronary artery disease. Siu D J Cardiovasc Med (Hagerstown); 2010 Jan; 11(1):1-6. PubMed ID: 19829140 [TBL] [Abstract][Full Text] [Related]
37. [Use of aspirin in coronary disease]. Montalescot G Presse Med; 1995 Jun; 24(20):925-7. PubMed ID: 7638141 [TBL] [Abstract][Full Text] [Related]
38. Aspirin and other antiplatelet drugs in the prophylaxis of thrombosis. Webster J; Douglas AS Blood Rev; 1987 Mar; 1(1):9-20. PubMed ID: 3332089 [TBL] [Abstract][Full Text] [Related]